

# Megan Othus

1100 Fairview Avenue North  
M3-C102  
PO Box 19024  
Seattle, WA 98109-1024

*Cell:* (503) 449-8943  
*Office:* (206) 667-5749  
mothus@fredhutch.org

---

## EDUCATION

**Harvard University**, Cambridge, MA

Ph.D., Biostatistics, June 2009

Dissertation: “Survival Analysis with Complex Censoring Mechanisms with Application in Population-based Studies and Clinical Trials”

Advisor: Yi Li

A.M., Biostatistics, June 2006

**Reed College**, Portland, OR

B.A., Mathematics, May 2004

Thesis: “An Analysis of the Relative Risk of Cancer Mortality Among Atomic Bomb Survivors”

Advisor: Albyn Jones

## PROFESSIONAL POSITIONS

Professor, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 2020–present

Affiliate Professor, Department of Biostatistics, University of Washington, Seattle, WA 2021–present

Associate Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 2014–2020

Affiliate Associate Professor, Department of Biostatistics, University of Washington, Seattle, WA 2015–present

Affiliate Assistant Professor, Department of Biostatistics, University of Washington, Seattle, WA 2011–2015

Assistant Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 2009–2014

## RESEARCH INTERESTS

Clinical trial design and analysis, survival analysis, cure modeling

## PROFESSIONAL ACTIVITY

Associate Editor, *Leukemia* 2022 – present

Statistical Advisor, *The Lancet Haematology* 2022 – present

Member, ASCO Scientific Program Committee 2022 – present

Council Member, International Biometric Society 2021 – present

Member, NIH Clinical Oncology (CONC) Study Section 2020 – present

Member, NCI Pediatric Leukemia/Lymphoma Steering Committee 2020 – present

Member, Children's Oncology Group DSMB	2018 – present
Faculty, ASH Clinical Research Training Institute	2016 – present
Member, NCI Correlative Sciences Steering Committee	2015 – 2021
Statistical Reviewer, Clinical Cancer Research	2014 – 2018
Member, NCI Leukemia Steering Committee	2013 – present
Member, HVTN Safety Monitoring Board	2012 – present
Secretary, WNAR	2012 – 2021
Organizer, SWOG Young Investigators Course	2011 – present

HONORS AND  
AWARDS

NCI Director's Award <i>National Cancer Institute</i>	2021
Hutch United Mentoring Award <i>Fred Hutchinson Cancer Research Center</i>	2021
Dr. Charles A. Coltman, Jr. Fellowship <i>Hope Foundation</i>	2011
Statistics in Epidemiology Student Travel Award <i>American Statistical Association</i>	2009
Byar Young Investigator Travel Award <i>American Statistical Association</i>	2008
Health Policy Statistics Student Paper Award <i>American Statistical Association</i>	2008
Distinguished Student Paper Award <i>International Biometric Society Eastern North American Region</i>	2008
Student Paper Award <i>International Chinese Statistics Association</i>	2008
Contributed Talk Award <i>Frontiers in Applied and Computational Mathematics</i>	2008
Certificate of Distinction in Teaching <i>Derek Bok Center for Teaching and Learning at Harvard University</i>	2008
Award for Best Teaching Assistant <i>Harvard School of Public Health</i>	2007
Certificate of Distinction in Teaching <i>Harvard University Department of Biostatistics</i>	2006–2007
Mu Sigma Rho	2007
Phi Beta Kappa	2004

PROFESSIONAL  
MEMBERSHIPS

American Society of Clinical Oncology (ASCO)	
American Statistical Association (ASA)	
American Society of Hematology (ASH)	
Western North American Region of the International Biometric Society (WNAR of IBS)	

## REFEREE

American Journal of Hematology, Blood, Blood Advances, BMC Anesthesiology, BMC Cancer, BMC Public Health, Biometrical Journal, Biometrics, Biostatistics, British Journal of Cancer, Cancer, Cancers, Clinical Cancer Research, Clinical Trials, Communications in Statistics - Simulation and Computation, Computational Statistics and Data Analysis, European Series in Applied and Industrial Mathematics: Probability and Statistics, Future Oncology, Haematologica, International Journal of Biostatistics, JAMA Oncology, JAMA Network OPEN, Journal of the American Statistical Association, Journal of Applied Statistics, Journal of Bioanalysis and Biostatistics, Journal of Clinical Oncology, Journal of Medical Economics, Journal of Multivariate Analysis, Journal of the National Cancer Institute, Journal of the Royal Statistical Society Series (JRSS) A, JRSSB, JRSSC, Journal of Translational Medicine, Lancet Haematology, Leukemia, Leukemia Research, Lifetime Data Analysis, Nature Medicine, Pharmaceutical Statistics, PLOS ONE, Science Translational Medicine, Statistics in Biosciences, Statistics in Medicine, Statistics and Probability Letters, Value in Health

## EXTRAMURAL

- Division of Biostatistics, Medical College of Wisconsin, March 2022

## PRESENTATIONS

- American Society of Hematology Annual Meeting, December 2021
- University of California San Diego, Biostatistics Seminar Series, November 2021
- University of Michigan, Cancer Biostatistics Seminar Series, September 2020
- International Clinical Biostatistics Society Annual Meeting, Virtual Meeting, August 2020
- American Association of Cancer Research, Virtual Meeting, June 2020
- American Society of Hematology Meeting, Orlando, FL, December 2019
- Society for Clinical Trials, New Orleans, LA, May 2019
- WNAR, Edmonton, Alberta, Canada, June 2018
- Addressing the Cancer Burden in Colombia through Clinical Trials Workshop, Bogota, Colombia, November 2018
- National Clinical Trials Network Statistics Meeting, Portland, OR, May 2018
- Workshop on Risk Modeling, Management and Mitigation in Health Sciences, Centre de Recherches Mathematiques, Montreal, Canada, December 2017
- Women in Statistics Conference, La Jolla, CA, October 2017
- Oishi Symposium, SWOG Group Meeting, San Francisco, CA, April 2017
- Instituto Nacional de Cancerologia, Bogota, Colombia, November 2016
- WNAR, Honolulu, HI, June 2014
- American Society of Hematology Annual Meeting, Atlanta, GA, December 2012
- Department of Mathematics, Reed College, Portland, OR, November 2012
- Society for the Advancement of Chicanos and Native Americans in Science National Conference, Seattle, WA, October 2012

- ENAR, Miami, FL, March 2011
- Department of Mathematics, Reed College, Portland, OR, December 2010
- International Conference on Statistics and Society, Beijing, China, July 2010
- Joint Statistical Meetings, Washington DC, August 2009
- New England Statistics Symposium, Storrs CT, April 2009
- Department of Mathematical and Statistical Sciences, University of Colorado, Denver, CO, February, 2009
- Department of Biostatistics and Informatics, University of Colorado, Denver, CO, February 2009
- Department of Biostatistics, University of Washington, Seattle, WA, February 2009
- Program in Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, WA, February 2009
- Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, February 2009
- Center for Statistical Sciences, Department of Community Health, Brown University, Providence, RI, January 2009
- Department of Biostatistics, UCLA, Los Angeles, CA, January 2009
- Joint Statistical Meetings, Denver, CO, August 2008
- International Chinese Statistical Association Applied Statistics Symposium, Piscataway, NJ, June 2008
- Frontiers of Applied and Computational Mathematics, Newark, NJ, May 2008
- ENAR, Arlington, VA, March 2008

#### INTRAMURAL PRESENTATIONS

- Clinical Trial Affinity Group, Fred Hutchinson Cancer Research Center, Seattle, WA, January 2018
- Prentice Science & Statistics Integrative Seminar, Fred Hutchinson Cancer Research Center, Seattle, WA, December 2017
- Cancer Research and Biostatistics, Seattle, WA, October 2017
- Clinical Trial Affinity Group, Fred Hutchinson Cancer Research Center, Seattle, WA, January 2017
- Department of Biostatistics, University of Washington, Seattle, WA, March 2011
- Clinical Trial Fellows Seminar Series, Beth Israel Deaconess Medical Center, Boston, MA, April 2008
- Clinical Trial Fellows Seminar Series, Beth Israel Deaconess Medical Center, Boston, MA, March 2008
- Cancer Working Group Seminar Series, Harvard, Biostatistics Department, Boston, MA, February 2008

BOOK  
CHAPTERS**Published**

1. **M. Othus**. Design and Analysis of Immunotherapy Clinical Trials. In: S. Halabi and S. Michiels (eds): Textbook of Clinical Trials in Oncology. 2019. Chapman & Hall/ CRC Press.
2. **M. Othus**, A. Mitchell, B. Barlogie, G. Morgan, J. Crowley. Cure-rate Survival Models and Their Application to Clinical Trials. In: Matsui, S, Crowley J (eds): Frontiers of Biostatistical Methods and Applications in Clinical Oncology. 2017. Springer.
3. **M. Othus**, J. Crowley, B. Barlogie. Cure-rate Survival Models in Clinical Trials. In: J. Crowley, A. Hoering (eds): Handbook of Statistics in Clinical Oncology (Edition 3). 2012. CRC Press.

## PAPERS

**Published or In Press**

1. O. Coentien, M. Byelykh, **M. Othus**, B. Sandmaier, G. Schock, C. Davis, F. Appelbaum, and R. Walter, "Relationship between pre-transplant nutritional status and outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation," *Transplantation and Cellular Therapy*, in press.
2. **M. Othus**, I. Thomas, X. Wang, C. Ariti, P. Mehta, M. Sydenham, R. Hills, A. Burnett, S. Nand, S. Assouline, L. Michaelis, H. Erba, N. Russel, K. Kerr, R. Walter, and M. Denis, "Early mortality risk with non-intensive acute myeloid leukemia (aml) therapies: Analysis of 1,336 patients from MRC/NCRI and SWOG," *Leukemia and Lymphoma*, in press.
3. E. Rodriguez-Arboli, **M. Othus**, C. Ovain, L. Zarling, B. Sandmaier, F. Milano, G. Schock, C. Davis, J. Deeg, F. Appelbaum, R. Storb, and W. R., "Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation," *Haematologica*, in press.
4. T. Nishath, X. Li, A. Chandramohan, **M. Othus**, X. Ji, *et al.*, "Risk factors Associated with abandonment of care in retinoblastoma: Analysis of 692 patients from 10 countries," *British Journal of Ophthalmology*, in press.
5. **M. Othus**, G. Garcia-Manero, J. Godwin, J. Weick, F. Appelbaum, H. Erba, and E. Estey, "Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data," *Haematologica*, in press.
6. J. Unger, A. Darke, **M. Othus**, T.-G. Truong, N. Khushalani, K. Kendra, K. Lewis, B. Faller, P. Funchain, E. Buchbinder, A. Tarhini, J. Kirkwood, E. Sharon, V. Sondak, S. Guild, K. Grossman, A. Ribas, and S. Patel, "Adjuvant pembrolizumab improves quality-of-life outcomes compared to high dose

- interferon or ipilimumab in patients with resected melanoma; SWOG S1404, A Randomized Clinical Trial,” *JAMA Oncology*, in press.
7. E. Rodriguez-Arboli, O. Coentn, **M. Othus**, and R. Walter, “Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation,” *Bone Marrow Transplantation*, in press.
  8. O. Coentn, J. Wilson, M. Fang, B. Sandmier, E. Rodriguez-Arboli, B. Wood, **M. Othus**, J. F. Appelbaum, and R. Walter, “Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia,” *Haematologica*, in press.
  9. O. Coentn, **M. Othus**, G. Johal, M. Hunault-Berger, F. Appelbaum, and R. Walter, “Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia,” *Leukemia*, in press. PMID: 35660798.
  10. C. Godwin, E. Rodriguez-Arboli, **M. Othus**, A. Halpern, J. Appelbaum, M.-B. Percival, P. Hendrie, V. Oehler, S. Keel, J. Abkowitz, J. Cooper, and R. Walter, “Phase 1/2 trial of CLAG-M with dose-escalated mitoxantrone in combination with fractionated-dose gemtuzumab ozogamicin for newly diagnosed acute myeloid leukemia and other high-grade myeloid neoplasms,” *Cancers*, 14(12), pages 2934, 2022. PMID: PMC9221325.
  11. L. Zarling, **M. Othus**, B. Sandmaier, F. Milano, G. Schoch, C. Davis, M. Bleakley, H. Deeg, F. Appelbaum, R. Storb, and R. Walter, “Utility of treatment-related mortality (TRM) score to predict outcomes for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation,” *Leukemia*, 36(6), pages 1563–1574, 2022. PMID: PMC9177780.
  12. X. Chen, A. Affinati, Y. Lee, A. Turcu, N. Henry, E. Schipou, A. Qin, **M. Othus**, D. Clauw, N. Ramnath, and L. Zhao, “Immune checkpoint inhibitors and risk of type I diabetes mellitus,” *Diabetes Care*, 45(5), pages 1170–1176, 2022. PMID: PMC9174959.
  13. A. Halpern, **M. Othus**, G. Alcorn, Z. Ali, K.-L. Garcia, M.-B. Percival, S. Keel, R. Cassaday, P. Becker, E. Estey, and R. Walter, “Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm,” *Leukemia*, 36(5), pages 1386–1389, 2022. PMID: 35173273.
  14. A. Advani, A. Moseley, L. O’Dwyer, B. Wood, M. Fang, M. Wieduwilt, I. Aldoss, J. Park, R. Klisovic, M. Baer, W. Stock, R. Bhave, **M. Othus**, R. Harvey, C. Willman, M. Litzow, S. R. E. Sharon, and E. H., “SWOG 1318: A Phase 2 trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia,” *Journal of Clinical Oncology*, 40(14), pages 1574–1582, 2022. PMID: PMC9084435.

15. N. Kompar, **M. Othus**, K. Gardner, C. Shaw, A. Halpern, B. Scott, P. Hendrie, R. Walter, P. Becker, E. Estey, and M.-B. Percival, “Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies,” *Leukemia*, 36pages 1164–1166, 2022. PMID: 35058596.
16. G. Paras, L. Morsink, **M. Othus**, F. Milano, B. Sandmaier, L. Zarling, R. Palmieri, G. Schoch, C. Davis, M. Bleakley, M. Flowers, H. Deeg, F. Appelbaum, R. Storb, and R. Walter, “Conditioning intensity and peri-transplant flow cytometric MRD dynamics in adult AML,” *Blood*, 139(11), pages 1694–1706, 2022. PMCID: PMC8931514.
17. **M. Othus**, M.-J. Zhang, and R. Gale, “Clinical trials: Design, endpoints and interpretation of outcomes,” *Bone Marrow Transplantation*, 57(3), pages 338–342, 2022. PMID: 34997213.
18. K. Grossman, **M. Othus**, S. Patel, A. Tarhini, V. Sondak, M. Knopp, T. Patrella, T.-G. Truong, N. Khushalani, J. Cohen, E. Buchbinder, K. Kendra, P. Funchain, K. Lewis, R. Conry, B. Chmielowski, R. Kudchardkar, D. Johnson, H. Li, J. Moon, Z. Eroglu, B. Gastman, M. Kovacsovics-Bankowski, K. Gunturu, S. Ebbinghaus, S. Ahsan, N. Ibrahim, E. Sharon, L. Korde, J. Kirkwood, and A. Ribas, “Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma,” *Cancer Discovery*, 12(3), pages 644–653, 2022. PMCID: PMC8904282.
19. A. Halpern, **M. Othus**, N. Howard, P. Hendrie, M.-E. Percival, G. Hartley, V. Welch, E. Estey, and R. Walter, “Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy,” *Leukemia and Lymphoma*, 63(1), pages 142–151, 2022. PMID: 34608844.
20. S. Adams, **M. Othus**, S. Patel, K. Miller, R. Chugh, S. Schuetz, M. Chamberlin, B. Haley, A. Storniolo, M. Reddy, S. Anderson, C. Zimmerman, A. O’Dea, J. Mirshahadi, H. amd Ahnert, F. Brescia, W. Hah, J. Raymond, D. Biggs, R. Connolly, E. Sharon, L. Korde, R. Gray, E. Mayerson, M. Plets, C. Blanke, Y. Kwang Chae, and R. Kurzrock, “A multicenter Phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: Cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609),” *Clinical Cancer Research*, 28(2), pages 271–278, 2022. PMCID: PMC8776596.
21. M.-E. M. Percival, **M. Othus**, S. Mirahsani, K. M. Gardner, C. Shaw, A. B. Halpern, P. S. Becker, P. C. Hendrie, M. L. Sorrow, R. B. Walter, *et al.*, “Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility,” *haematologica*, 106(8), pages 2114, 2021. PMCID: PMC8327712.
22. J. Moon, M. LeBlanc, and **M. Othus**, “Accounting for all patients in waterfall plots,” *JCO Clinical Cancer Informatics*, 5pages 414–420, 2021. PMCID: PMC8240789.

23. N. J. Moore, **M. Othus**, A. B. Halpern, N. P. Howard, L. Tang, K. E. Bastys, M.-E. M. Percival, P. C. Hendrie, G. A. Hartley, V. L. Welch, *et al.*, “Financial implications of early hospital discharge after AML-like induction chemotherapy: A 4-year retrospective analysis,” *Journal of the National Comprehensive Cancer Network*, 1(aop), pages 1–10, 2021. PMID: 34161925.
24. Y. Wang, S. Liu, Z. Yang, A. Algazi, S. Lomeli, Y. Wang, **M. Othus**, A. Hong, X. Wang, C. Randolph, A. Jones, M. Bosenberg, S. Byrum, A. Tackett, H. Lopez, C. Yates, D. Solit, A. Ribas, M. Piva, G. Moriceau, and R. Lo, “Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy,” *Cancer Cell*, 39(10), pages 1375–1387, 2021. PMID: 34416167.
25. M. Wagner, **M. Othus**, S. Patel, C. Ryan, A. Sangal, B. Power, G. Budd, A. Victor, C.-T. Hseuh, R. Chugh, S. Nair, K. Leu, M. Agulnik, E. Sharon, E. Mayerson, M. Plets, C. Blanke, H. Streicher, Y. Chae, and R. Kurzrock, “A multicenter phase II trial (SWOG S1609, cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a sub-Study of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART),” *Journal for ImmunoTherapy of Cancer*, 9(8), pages e002990, 2021. PMCID: PMC8330584.
26. S. Selular, S. May, D. Law, and **M. Othus**, “Stratified randomization for platform trials with differing experimental arm eligibility,” *Clinical Trials*, 18(5), pages 562–569, 2021. PMCID: PMC8478711.
27. S. Patel, E. Mayerson, Y. Kwang Chae, J. Strosberg, J. Wang, B. Konda, J. Hayward, C. McLeod, H. Chen, S. Sharon, **M. Othus**, C. Ryan, M. Plets, C. Blanke, and R. Kurzrock, “A phase ii basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort,” *Cancer*, 127(17), pages 3194–3201, 2021. PMID: 33882143.
28. **M. Othus**, G. Garcia-Manero, J. Godwin, J. Weick, D. Stirewalt, F. Appelbaum, H. Erba, and E. Estey, “Associations between complete remission and 2-3 year survival following 7+3 induction for acute myeloid leukemia,” *Leukemia & Lymphoma*, 62(8), pages 1967–1972, 2021. PMID: 33719833.
29. M. Hochman, **M. Othus**, R. Walter, C. Shaw, K. Gardner, M.-E. Percival, P. Hendrie, B. Sandmaier, and E. Estey, “Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (aml),” *Leukemia & Lymphoma*, 62(6), pages 1532–1535, 2021. PMID: 33752557.
30. A. Moseley, **M. Othus**, G. Garcia-Manero, F. Appelbaum, H. Erba, and R. Walter, “Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of swog cancer research network trials S0106 and S1203,” *Leukemia & Lymphoma*, 62(7), pages 1774–1777, 2021. PMID: 33560164.
31. X. Chen, **M. Othus**, B. Wood, R. Walter, P. Becker, M.-B. Percival, J. Abkowitz, F. Appelbaum, and E. Estey, “Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome



- with excess blasts and secondary acute myeloid leukemia,” *Leukemia & Lymphoma*, 62(5), pages 1226–1233, 2021. PMID: 33345655.
32. A. Halpern, **M. Othus**, N. Howard, P. Hendrie, M.-E. Percival, B. Scott, T. Gernsheimer, N. Baclig, S. Buckley, R. Cassady, G. Hartley, V. Welch, E. Estey, and R. Walter, “Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms,” *Leukemia and Lymphoma*, 62(1), pages 234–238, 2021. PMID: 32921204.
  33. R. Palmieri, **M. Othus**, A. Halpern, M.-E. Percival, C. Godwin, P. Becker, and R. Walter, “Accuracy of SIE/SIES/GITMO consensus criteria for unfitnes to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm,” *Journal of Clinical Oncology*, 38(35), pages 4163–4174, 2020. PMID: 33030979.
  34. L. Morsink, B. Sandmaier, **M. Othus**, R. Palmieri, N. Granot, E. Bezerra, B. Wood, M. Mielcarek, G. Schoch, C. Davis, M. Flowers, H. Deeg, F. Appelbaum, R. Storb, and R. Walter, “Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation,” *Cancers*, 12(9), pages 2339–2339, 2020. PMCID: PMC7565021.
  35. A. Algazi, **M. Othus**, A. Daud, R. Lo, J. Mehnert, T.-G. Truong, R. Conry, K. Kendra, G. Doolittle, J. Clark, M. Messino, D. Moore, C. Lao, B. Faller, R. Govindarajan, A. Harker-Murray, L. Dreisbach, J. Moon, K. Grossman, and A. Ribas, “Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF mutated melanoma: A randomized phase 2 trial,” *Nature Medicine*, 26(10), pages 1564–1568, 2020. PMID: 33020646.
  36. M. Sorrow, S. Agarwal, **M. Othus**, Y. Lynch, J. Nyland, M.-E. Percival, P. Becker, F. Appelbaum, and E. Estey, “Regimen-intensity per count-recovery and hospitalization (RICH) index: A new tool to assign degree of intensity to regimens used to treat acute myeloid leukemia,” *Cancer Medicine*, 9(18), pages 6515–6523, 2020. PMCID: PMC7520345.
  37. N. Epperla, J. Vaughn, **M. Othus**, A. Hallack, and L. Costa, “Recent survival trends in diffuse large B-cell lymphoma – have we made any progress beyond rituximab?,” *Cancer Medicine*, 9(15), pages 5519–5525, 2020. PMCID: PMC7402846.
  38. D. Grossman, N. Okwundu, E. Bartlett, M. Marchetti, **M. Othus**, D. Coit, R. Hartman, S. Leachman, E. Berry, L. Korde, S. Lee, M. Bar-Eli, M. Berwick, T. Bowles, E. Buchbinder, E. Burton, E. Chu, C. Curiel-Lewandrowski, J. Curtis, A. Daud, D. Deacon, L. Ferris, J. Gershenwald, K. Grossman, S. Hui-Lieskovan, J. Hyngstrom, J. Jeter, R. Judson-Torres, K. Kendra, C. Kim, J. Kirkwood, D. Lawson, P. Leming, G. Long, A. Marhhoob, J. Mehnert, M. Ming, K. Nelson, D. Polsky, R. Scolyer, E. Smith, V. Sondak, M. Stark, J. Stein, J. Thompson, T. JF, S. Venna, M. Wei, and S. Swetter, “Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge

- gaps and assessing the clinical benefit: Melanoma prevention working group consensus statement,” *JAMA Dermatology*, 156(9), pages 1004–1011, 2020. PMID: 32725204.
39. **M. Othus**, A. Bansal, H. Erba, and S. Ramsey, “Bias in mean survival from fitting cure models with limited follow-up,” *Value in Health*, 23(8), pages 1034–1039, 2020. PMID: PMC7446760.
  40. S. P. Patel, **M. Othus**, Y. K. Chae, R. Kurzrock, S. Team, *et al.*, “Ipilimumab and nivolumab in rare tumors s1609: Neuroendocrine - response (letter),” *Clinical cancer research: an official journal of the American Association for Cancer Research*, 26(10), pages 2434, 2020.
  41. R. Palmieri, S. Buckley, **M. Othus**, A. Halpern, M.-B. Percival, B. Scott, P. Hendrie, P. Becker, V. Oehler, E. Estey, and R. Walter, “Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm,” *Leukemia and Lymphoma*, 61(7), pages 1728–1731, 2020. PMID: PMC7384960.
  42. S. Patel, **M. Othus**, Y. Chae, F. Giles, D. Hansel, P. Singh, A. Fontaine, M. Shah, A. Kasi, T. Al Baghdadi, M. Matrana, Z. Gatalica, W. Korn, J. Hayward, C. McLeod, H. Chen, E. Sharon, E. Mayerson, C. Ryan, M. Plets, C. Blanke, and C. Kurzrock, “A phase II basket trial of Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The non-pancreatic neuroendocrine cohort,” *Clinical Cancer Research*, 26(10), pages 2290–2296, 2020. PMID: PMC7231627.
  43. L. Morsink, **M. Othus**, E. Bezerra, B. Wood, M. Fang, B. Sandmaier, M. Mielcarek, G. Schoch, R. Storb, J. Deeg, F. Appelbaum, and R. Walter, “Impact of pre-transplant measurable residual disease on outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype aml,” *Leukemia*, 34(6), pages 1577–1587, 2020. PMID: PMC7272254.
  44. L. Morsink, E. Bezerra, **M. Othus**, B. Wood, M. Fang, B. Sandmaier, M. Mielcarek, H. Deeg, G. Schoch, F. Appelbaum, and R. Walter, “Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease,” *Leukemia*, 36(6), pages 1701–1705, 2020. PMID: PMC7266710.
  45. J. Pagel, **M. Othus**, G. Garcia-Manero, M. Fang, J. Radich, D. Rizzieri, G. Marcucci, S. Strickland, M. Litzow, M. Savoie, S. Spellman, D. Confer, J. Chell, M. Brown, B. Medeiros, M. Sekeres, T. Lin, G. Uy, B. Powell, R. Bayer, R. Larson, R. Stone, D. Claxton, J. Essell, S. Luger, S. Mohan, A. Moseley, H. Erba, and F. Appelbaum, “Rapid donor identification improves survival in high risk first remission AML patients,” *JCO Oncology Practice*, 16(6), pages e464–e475, 2020. PMID: PMC7291544.

46. J. Lancet, A. Moseley, R. Komrokji, S. Coutre, D. DeAngelo, **M. Othus**, M. Tallman, M. Litzow, H. Erba, and A. F., “A phase II study of ATRA, arsenic trioxide and gemtuzumab ozogamicin in patients with previously untreated high-risk acute promyelocytic leukemia (SWOG S0535),” *Blood Advances*, 4(8), pages 1683–1689, 2020. PMCID: PMC7189292.
47. A. Michelson, S. McDonough, C. Willman, E. Koegle, J. Godwin, S. Petersdorf, A. List, **M. Othus**, F. Appelbaum, J. Radich, M. Ganapathi, A. Advani, and R. Ganapathi, “Association of immunophenotype with expression of topoisomerase II  $\alpha$  and  $\beta$  in adult acute myeloid leukemia,” *Scientific Reports*, 10(1), pages 5846–5846, 2020. PMCID: PMC7099013.
48. S. Buckley, A. Halpern, **M. Othus**, D. Jimenez-Sahagun, R. Walter, and S. Lee, “Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia,” *Leukemia and Lymphoma*, 61(5), pages 1158–1167, 2020. PMID: 31909637.
49. A. Hoffman, A. Besch, **M. Othus**, L. Morsink, B. Wood, M. Mielcarek, F. Appelbaum, and E. Estey, “Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia,” *Bone Marrow Transplantation*, 55(3), pages 669–672, 2020. PMID: 31685932.
50. E. Estey, J. Karp, A. Emadi, **M. Othus**, and R. Gale, “Recent drug approvals for newly-diagnosed acute myeloid leukemia: Gifts or a trojan horse? (letter),” *Leukemia*, 34(3), pages 671–681, 2020. PMID: 31915366.
51. **M. Othus**, R. Gale, C. Hourigan, and R. Walter, “Statistics and measurable residual disease (MRD)-testing: Uses and abuses in hematopoietic cell transplantation,” *Bone Marrow Transplantation*, 55(5), pages 843–850, 2020. PMCID: PMC7462748.
52. A. Halpern, N. Howard, **M. Othus**, P. Hendrie, N. Baclig, S. Buckley, M.-B. Percival, P. Becker, B. Scott, V. Oehler, T. Gernsheimer, S. Keel, J. Orozco, R. Cassady, A. Shustov, G. Hartley, V. Welch, E. Estey, and R. Walter, “Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm,” *Leukemia*, 34(2), pages 635–639, 2020. PMID: 31586148.
53. E. D. Bezerra, **M. Othus**, C. Shawn, M.-E. Percival, K. Gardner, R. B. Walter, P. S. Becker, P. C. Hendrie, and E. H. Estey, “Independent associations between glomerular filtration rate and serum bilirubin level and early mortality in acute myeloid leukemia,” *Clinical Lymphoma, Myeloma and Leukemia*, 19(12), pages e633–e635, 2019. PMID: 31648955.
54. C. Ustun, J. Le-Rademacher, H.-L. Wang, **M. Othus**, Z. Sun, B. Major, M.-J. Zhang, E. Storrick, J. Lafky, S. Chow, K. Mrozek, E. Attar, S. Nand, C. Bloomfield, L. Cripe, M. Tallman, F. Appelbaum, R. Larson, G. Marcucci, G. Roboz, G. Uy, R. Stone, A. Jatoi, T. Shea, M. de Lima, J. Foran, B. Sandmaier, M. Litzow, H. Erba, H. Hurria, D. Weisdorf, and A. Artz, “Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in

- older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study,” *Leukemia*, 33(11), pages 2599–2609, 2019. PMID: PMC6842042.
55. C. Godwin, J. Fromm, **M. Othus**, B. Sandmaier, M. Mielcarek, B. Wood, F. Appelbaum, R. Storb, , and R. Walter, “Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission,” *Bone Marrow Transplantation*, 54(9), pages 1511–1514, 2019. PMID: PMC6708776.
  56. S. Buckley, N. Mark, **M. Othus**, E. Estey, K. Patel, and R. Walter, “Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms,” *Leukemia and Lymphoma*, 60(9), pages 2304–2307, 2019. PMID: PMC6739192.
  57. A. Nazha, M. A. Sekeres, R. Bejar, M. J. Rauh, **M. Othus**, R. S. Komrokji, J. Barnard, C. B. Hilton, C. M. Kerr, D. P. Steensma, *et al.*, “Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence,” *JCO precision oncology*, 3pages 1–11, 2019. PMID: PMC6818517.
  58. B. Medeiros, **M. Othus**, M. Tallman, Z. Sun, H. Fernandez, J. Rowe, H. Lazarus, F. Appelbaum, S. Luger, M. Litzow, and H. Erba, “The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ ECOG-ACRIN Study (S0106 and E1900),” *Leukemia Research*, 78(-), pages 29–33, 2019. PMID: PMC6615032.
  59. E. Estey, **M. Othus**, and R. Gale, “New study-designs to address the clinical complexity of acute myeloid leukemia,” *Leukemia*, 33(3), pages 567–569, 2019. PMID: 30670784.
  60. A. Halpern, **M. Othus**, E. Huebner, B. Scott, P. Hendrie, M.-B. Percival, P. Becker, H. Smith, V. Oehler, J. Orozco, R. Cassady, K. Gardner, T. Chen, S. Buckley, K. Orlowski, A. Anwar, E. Estey, and R. Walter, “Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory AML or other high-grade myeloid neoplasms,” *Haematologica*, 104(4), pages e143–e146, 2019. PMID: PMC6442971.
  61. **M. Othus**, M. Sekeres, S. Nand, G. Garcia-Manero, F. Appelbaum, H. Erba, and E. Estey, “Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: An analysis of four SWOG studies,” *Leukemia*, 33(2), pages 371–378, 2019. PMID: PMC6367029.
  62. **M. Othus**, E. Estey, G. Garcia-Manero, B. Wood, D. Stirewalt, J. Godwin, J. Weick, J. Anderson, F. Appelbaum, H. Erba, and R. Walter, “Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: Analysis of recent SWOG trials,” *Leukemia*, 33(2), pages 554–558, 2019. PMID: PMC6367002.

63. S. A. Buckley, M.-E. Percival, **M. Othus**, A. B. Halpern, E. M. Huebner, P. S. Becker, C. Shaw, M. Shadman, R. B. Walter, and E. H. Estey, “A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study,” *Leukemia & lymphoma*, 60(4), pages 1023–1029, 2019.
64. A. Halpern, **M. Othus**, E. Huebner, B. Scott, P. Becker, M.-B. Percival, P. Hendrie, K. Gardner, S. Buckley, K. Orlowski, A. Anwar, F. Appelbaum, H. Erba, E. Estey, and R. Walter, “Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms,” *Leukemia*, 32(11), pages 2352–2362, 2018. PMID: PMC6192860.
65. Y. Zhou, **M. Othus**, R. Walter, E. Estey, D. Wu, and B. Wood, “Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-mutated AML,” *Biology of Blood and Marrow Transplantation*, 24(8), pages 1615–1620, 2018. PMID: 29684564.
66. A. Statler, **M. Othus**, H. Erba, T. Chauncy, J. Radich, C. Coutre, A. Advani, S. Nand, F. Ravandi, S. Mukerjee, and M. Sekeres, “Comparable outcomes of patients eligible versus ineligible for SWOG leukemia studies,” *Blood*, 131(25), pages 2782–2788, 2018. PMID: PMC6014358.
67. A. Advani, H. Li, L. Michaelis, B. Medeiros, M. Liedtke, A. List, K. O’Dwyer, **M. Othus**, H. Erba, and F. Appelbaum, “Report of the relapsed/ refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia,” *Leukemia Research*, 67(-), pages 17–20, 2018. PMID: PMC6574123.
68. R. Walter, L. Michaelis, **M. Othus**, G. Uy, J. Radich, R. Little, S. Hita, L. Saini, J. Foran, A. Gerds, H. Klenpin, A. Hay, S. Assouline, J. Lancet, S. Couban, M. Litzow, R. Stone, and H. Erba, “Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia,” *American Journal of Hematology*, 93(2), pages E49–E52, 2018. PMID: PMC5760282.
69. R. Walter, **M. Othus**, K. Orlowski, E. McDaniel, B. Scott, P. Becker, M.-B. Percival, P. Hendrie, B. Medeiros, M. Chiarella, A. Louie, and E. Estey, “Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm,” *Haematologica*, 103(3), pages e106–e109, 2018. PMID: PMC5830380.
70. E. Pogossova-Agadjanyan, A. Moseley, **M. Othus**, F. Appelbaum, T. Chauncey, I. Chen, H. Erba, J. Godwin, M. Fang, K. Kopecky, A. List, G. Pogosov, J. Radich, C. Willman, B. Wood, S. Meshinchi, and D. Stirewalt, “Impact of specimen heterogeneity on biomarkers in repository samples from patients with AML: A SWOG report,” *Biopreservation and Biobanking*, 16(1), pages 42–52, 2018. PMID: PMC5808392.

71. S. Buckley, D. Sahagun, **M. Othus**, R. Walter, and S. Lee, “Quality of life from the acute myeloid leukemia patient’s perspective,” *Cancer*, 124(1), pages 145–152, 2018. PMID: PMC5749925.
72. W. Samlowski, J. Moon, M. Witter, M. Atkins, J. Kirkwood, **M. Othus**, A. Ribas, V. Sondak, and L. Flaherty, “High frequency of brain metastases after adjuvant therapy for high risk melanoma,” *Cancer Medicine*, 6(11), pages 2576–2585, 2017. PMID: PMC5673911.
73. S. A. Buckley, B. L. Wood, **M. Othus**, C. S. Hourigan, C. Ustun, M. A. Linden, T. E. DeFor, M. Malagola, C. Anthias, V. Valkova, *et al.*, “Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis,” *haematologica*, 102(5), pages 865, 2017. PMID: PMC5477605.
74. A. Halpern, **M. Othus**, E. Huebner, S. Buckley, E. Pogossova-Agadjanyan, K. Orlowski, B. Scott, P. Becker, P. Hendrie, T. Chen, M.-B. Percival, E. Estey, D. Stirewalt, and R. Walter, “Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study,” *Leukemia*, 31(12), pages 2560–2567, 2017. PMID: PMC5709258.
75. E. Korn, **M. Othus**, T. Chen, and B. Freidlin, “Assessing treatment efficacy in the subset of responders in a randomized clinical trial,” *Annals of Oncology*, 28(7), pages 1640–1647, 2017. PMID: PMC5834152.
76. M. Sekeres, **M. Othus**, A. List, O. Odenike, R. Stone, S. Gore, M. Litzow, R. Buckstein, M. Fang, D. Roulston, C. Bloomfield, A. Mosely, A. Nazha, Y. Zhang, M. Velasco, R. Gaur, E. Atallah, E. Attar, E. Cook, A. Cull, M. Rauh, F. Appelbaum, and H. Erba, “A randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup study SWOG S1117,” *Journal of Clinical Oncology*, 35(24), pages 2745–2753, 2017. PMID: PMC5562170.
77. X. Chen, **M. Othus**, B. Wood, R. Walter, M.-E. Percival, P. Becker, P. Hendrie, F. Appelbaum, and E. Estey, “Flow cytometric demonstration of decrease in bone marrow leukemic blasts after ‘day 14’ without further therapy in acute myeloid leukemia,” *Leukemia and Lymphoma*, 58(11), pages 2717–2719, 2017. PMID: 28351184.
78. S. Buckley, B. Wood, **M. Othus**, C. Hourigan, C. Ustun, M. Linden, T. DeFor, M. Malagola, C. Anthias, V. Valkova, C. Kanakary, B. Gruhn, F. Bucisano, B. Devine, and R. Walter, “Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis,” *Haematologica*, 102(5), pages 865–873, 2017. PMID: PMC5477605.
79. O. Sala Torra, **M. Othus**, D. Williamson, B. Wood, I. Kirsch, H. Robins, L. Beppu, M. O’Donnell, S. Forman, F. Appelbaum, and J. Radich, “Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients,”

- Biology and Bone Marrow Transplantation*, 23(4), pages 691–696, 2017. PMID: PMC5465962.
80. S. Mantha, G. Goldman, S. Devlin, J. Lee, D. Zannino, M. Collins, D. Douer, H. Iland, M. Litzow, E. Stein, F. Appelbaum, R. Larson, R. Stone, B. Powell, S. Geyer, K. Laumann, J. Rowe, H. Erba, S. Coutre, **M. Othus**, J. Park, and M. Tallman, “Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era,” *Blood*, 129(13), pages 1763–1767, 2017. PMID: PMC5374291.
  81. **M. Othus**, A. Bansal, L. Koepl, S. Wagner, and S. Ramsey, “Accounting for cured patients in cost-effectiveness analysis,” *Value in Health*, 20(4), pages 705–709, 2017. PMID: 28408015.
  82. F. Ravandi, **M. Othus**, S. O’Brien, S. Forman, C. Ha, J. Wong, M. Tallman, E. Paietta, J. Racevskis, G. Uy, M. Horowitz, N. Takebe, R. Little, U. Borata, P. Kebriaei, L. Kingsbury, H. Kantargian, J. Radich, H. Erba, and F. Appelbaum, “US Intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL,” *Blood Advances*, 1(3), 2017. PMID: PMC5642915.
  83. X. Qu, **M. Othus**, J. Davison, Y. Wu, L. Yan, S. Meshinchi, F. Ostronoff, E. H. Estey, J. P. Radich, H. P. Erba, *et al.*, “Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials,” *Cancer*, 123(13), pages 2472–2481, 2017. PMID: PMC5705230.
  84. B. Freidlin, **M. Othus**, and E. Korn, “Information time scales for interim analyses of randomized clinical trials,” *Clinical Trials*, 13(4), pages 391–399, 2016. PMID: 27136947.
  85. **M. Othus**, B. Wood, D. Stirewalt, E. Estey, S. Petersdorf, F. Appelbaum, H. Erba, and R. Walter, “Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia,” *Leukemia*, 30(10), pages 2080–2083, 2016. PMID: PMC5053842.
  86. C. Delaney, M. Filippo, L. Cicconi, **M. Othus**, P. Becker, V. Sandu, I. Niccoud, A. Dahlberg, I. Bernstein, F. Appelbaum, and E. Estey, “Infusion of a non-HLA matched ex vivo expanded cord blood progenitor cell product after intensive AML chemotherapy: Report of a phase I trial,” *Lancet Haematology*, 3(7), pages e330–e339, 2016. PMID: 27374466.
  87. **M. Othus**, W. van Putten, B. Lowenberg, S. Petersdorf, S. Nand, H. Erba, F. Appelbaum, R. Hills, N. Russell, A. Burnett, and E. Estey, “Relationship between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVN/SAKK, and MRC/NCRI,” *Haematologica*, 101(7), pages e284–e286, 2016. PMID: PMC5004473.
  88. D. Wu, M. Miyaji, **M. Othus**, and B. Wood, “Clinical experience with modified, single-tube TCR V-beta flow cytometry analysis for T-cell clonality,” *American Journal of Clinical Pathology*, 145(4), pages 467–485, 2016. PMID: 27149025.

89. **M. Othus**, S. Mukherjee, M. Sekeres, J. Godwin, S. Petersdorf, F. Appelbaum, H. Erba, and E. Estey, "Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course," *Leukemia*, 30(8), pages 1779–1780, 2016. PMID: PMC4980556.
90. Y. Zhou, **M. Othus**, D. Araki, B. Wood, J. Radich, A. Halpern, M. Mielcarak, E. Estey, F. Appelbaum, and R. Walter, "Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia," *Leukemia*, 30(7), pages 1456–1464, 2016. PMID: PMC4935622 .
91. C. Godwin, **M. Othus**, M. Powell, S. Buckley, E. Estey, and R. Walter, "Prediction of early death in adults with relapsed or refractory acute myeloid leukemia," *Leukemia & Lymphoma*, 57(10), pages 2421–2424, 2016. PMID: PMC5003083.
92. N. Achille, **M. Othus**, K. Phelan, S. Zhang, K. Cooper, J. Godwin, F. Appelbaum, J. Radich, H. Erba, S. Nand, and N. Zeleznik-Le, "Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients," *Leukemia Research*, 42(-), pages 68–74, 2016. PMID: PMC4779662.
93. D. Araki, B. Wood, **M. Othus**, J. Radich, A. Halpern, Y. Zhuo, E. Estey, F. Appelbaum, and R. Walter, "Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Is it time to move toward a minimal residual disease-based definition of complete remission?," *Journal of Clinical Oncology*, 34(4), pages 329–336, 2016. PMID: PMC4872033.
94. E. Estey, **M. Othus**, S. Lee, F. Appelbaum, and R. Gale, "New drug approvals in acute myeloid leukemia: What's the best endpoint?," *Leukemia*, 30(3), pages 521–525, 2016. PMID: PMC4777773.
95. J. Vaughn, **M. Othus**, M. Powell, K. Gardner, D. Rizzuto, P. Hendrie, P. Becker, P. Pottinger, E. Estey, and R. Walter, "Comparative analysis of resource utilization and safety of outpatient management following intensive AML induction/salvage chemotherapy," *JAMA Oncology*, 1(8), pages 1120–1127, 2015. PMID: PMC4720981.
96. R. Walter, **M. Othus**, B. Lowenberg, G. Ossenkoppele, S. Petersdorf, T. Pabst, M.-C. Vekemans, F. Appelbaum, H. Erba, and E. Estey, "Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: Analysis of 1,892 patients from HOVON/SAKK and SWOG," *Haematologica*, 100(10), pages e409–e411, 2015. PMID: PMC4591777.
97. M. Bar, **M. Othus**, H. Park, V. Sandu, X. Chen, B. Wood, and E. Estey, "Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission," *Leukemia & Lymphoma*, 56(11), pages 3109–3115, 2015. PMID: PMC4714707.
98. D. Araki, **M. Othus**, R. Walter, V. Sandhu, B. Sandmaier, P. Becker, F. Appelbaum, and E. Estey, "Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival



- in acute myeloid leukemia,” *Haematologica*, 100(7), pages e254–e256, 2015. PMID: PMC4486235.
99. R. Walter, **M. Othus**, E. Paietta, J. Racevskis, H. Fernandez, J.-W. Lee, Z. Sun, M. Tallman, J. Patel, M. Gonen, O. Abdel-Wahab, R. Levine, and E. Estey, “Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia,” *Leukemia*, 29(10), pages 2104–2107, 2015. PMID: PMC4573365.
  100. S. Buckley, **M. Othus**, E. Estey, and R. Walter, “The treatment related mortality (TRM) score is associated with non-fatal adverse events following intensive AML induction chemotherapy,” *Blood Cancer Journal*, 5(-), pages e276, 2015. PMID: 25635529.
  101. S. Lee, J. Moon, B. Redman, T. Chidiac, L. Flaherty, Y. Zha, **M. Othus**, A. Ribas, V. Sondak, T. Gajewski, and K. Margolin, “A phase II study of RO4929097 gamma-secretase inhibitor in metastatic melanoma: SWOG 0933,” *Cancer*, 121(3), pages 432–440, 2015. PMID: PMC4304973.
  102. B. Medeiros, **M. Othus**, M. Fang, F. Appelbaum, and H. Erba, “Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia,” *Haematologica*, 100(3), pages 331–335, 2015. PMID: PMC4349271.
  103. F. Ostronoff, **M. Othus**, M. Lazenby, E. Estey, F. Appelbaum, A. Evans, J. Godwin, A. Gilkes, K. Kopecky, A. Burnett, A. List, M. Fang, V. Oehler, S. Petersdorf, E. Pogossova-Agadjanyan, J. Radich, C. Willman, S. Meshinchi, and D. Stirewalt, “Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: A SWOG and MRC/NCRI report,” *Journal of Clinical Oncology*, 33(10), pages 1157–1164, 2015. PMID: PMC4372852.
  104. P. Becker, B. Medeiros, A. Stein, **M. Othus**, F. Appelbaum, S. Forman, B. Scott, P. Hendrie, K. Gardner, J. Pagel, R. Walter, C. Parks, B. Wood, J. Abkowitz, and E. Estey, “G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm,” *American Journal of Hematology*, 90(4), pages 295–300, 2015. PMID: 25545153.
  105. M. Bar, W. Tong, **M. Othus**, K. Loeb, and E. Estey, “Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation,” *Biology of Blood and Marrow Transplantation*, 21(3), pages 546–551, 2015. PMID: 25545726.
  106. **M. Othus**, F. Appelbaum, P. Petersdorf, K. Kopecky, M. Slovak, T. Nevill, J. Brandwein, R. Larson, P. Stiff, R. Walter, M. Tallman, and H. Erba, “The fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy,” *Biology of Blood and Marrow Transplantation*, 21(3), pages 559–564, 2015. PMID: PMC4386840.
  107. R. Walter, **M. Othus**, A. Burnett, B. Lowenberg, H. Kamtarjian, G. Ossenkoppele, R. Hills, F. Ravandi, T. Pabst, A. Evans, S. Pierce, M. Vekemans, F. Appelbaum, and E. Estey, “Resistance prediction in AML: Analysis of 4,601 patients

- from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center,” *Leukemia*, 29(2), pages 312–320, 2015. PMID: PMC4318722.
108. R. Walter, G. Laszlo, J. Lionberger, J. Pollard, K. Harrington, C. Gudgeon, **M. Othus**, S. Rafii, S. Meshinchi, F. Appelbaum, *et al.*, “Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia,” *Leukemia*, 28(10), pages 1969–1977, 2014. PMID: PMC4167978.
  109. L. E. Flaherty, **M. Othus**, M. B. Atkins, R. J. Tuthill, J. A. Thompson, J. T. Vetto, F. G. Haluska, A. S. Pappo, J. A. Sosman, B. G. Redman, *et al.*, “Southwest Oncology Group S0008: A phase III trial of high-dose Interferon alfa-2b versus Cisplatin, Vinblastine, and Dacarbazine, plus Interleukin-2 and Interferon in patients with high-risk melanoma: An Intergroup study of Cancer and Leukemia Group B, Children’s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group,” *Journal of Clinical Oncology*, 32(33), pages 3771–3778, 2014. PMID: PMC4226807.
  110. R. Hills, S. Castaigne, F. Applebaum, J. Delaunay, S. Petersdorf, **M. Othus**, E. Estey, H. Dombret, S. Chevret, N. Ifrah, J.-Y. Cahn, C. Recher, L. Chilton, A. Moorman, and A. Burnett, “Addition of Gemtuzumab Ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials,” *Lancet Oncology*, 15(9), pages 986–996, 2014. PMID: PMC4137593.
  111. A. Advani, S. McDonough, E. Copelan, C. Willman, D. Mulford, A. List, M. Sekeres, **M. Othus**, H. Erba, and F. Appelbaum, “SWOG0919: A Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia,” *British Journal of Haematology*, 167(2), pages 233–237, 2014. PMID: PMC4188732.
  112. F. Ostronoff, **M. Othus**, R. Gerbing, M. Loken, S. Raimondi, B. Hirsch, B. Lange, S. Petersdorf, J. Radich, F. Appelbaum, A. Gamis, T. Alonzo, and S. Meshinchi, “NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: A COG and SWOG report,” *Blood*, 124(15), pages 2400–2407, 2014. PMID: PMC419275.
  113. W. Carson, J. Unger, J. Sosman, L. Flaherty, R. Tuthill, M. Porter, P. Terasaki, J. Thompson, R. Kempf, **A. M. Othus**, Ribas, and V. Sondak, “Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: Long-term outcome and impact of HLA class I antigen expression on overall survival,” *Cancer Immunology Research*, 2(10), pages 981–987, 2014. PMID: PMC4185232.
  114. S. A. Buckley, **M. Othus**, V. Vainstein, J. L. Abkowitz, E. H. Estey, and R. B. Walter, “Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes,” *American Journal of Hematology*, 89(4), pages 423–428, 2014. PMID: PMC4391649.
  115. A. S. Advani, S. McDonough, S. Coutre, B. Wood, J. Radich, M. Mims, M. O’Donnell, S. Elkins, M. Becker, **M. Othus**, and F. R. Appelbaum,

- “SWOG S0910: A phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia,” *British Journal of Haematology*, 165(4), pages 504–509, 2014. PMID: PMC4188732.
116. S. E. Coutre, **M. Othus**, B. Powell, C. L. Willman, W. Stock, E. Paietta, D. Levitan, M. Wetzler, E. C. Attar, J. K. Altman, S. D. Gore, T. Maher, K. J. Kopecky, M. S. Tallman, R. A. Larson, and F. R. Appelbaum, “Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy,” *British Journal of Haematology*, 165(4), pages 497–503, 2014. PMID: PMC4064464.
  117. B. C. Medeiros, **M. Othus**, E. H. Estey, M. Fang, and F. R. Appelbaum, “Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia,” *British Journal of Haematology*, 164(2), pages 245–250, 2014. PMID: PMC4117470.
  118. H. P. Erba, **M. Othus**, R. B. Walter, M. H. Kirschbaum, M. S. Tallman, R. A. Larson, M. L. Slovak, K. J. Kopecky, H. M. Gundacker, and F. R. Appelbaum, “Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432,” *Leukemia Research*, 38(3), pages 329–333, 2013. PMID: PMC4247790.
  119. **M. Othus**, H. Kantarjian, S. Petersdorf, F. Ravandi, J. Godwin, J. Cortes, S. Pierce, H. Erba, S. Faderl, F. Appelbaum, and E. Estey, “Declining rates of treatment-related mortality in patients with newly diagnosed AML given “intense” induction regimens: A report from SWOG and MD Anderson,” *Leukemia*, 28(2), pages 289–292, 2013. PMID: 23760400.
  120. S. Nand, **M. Othus**, J. E. Godwin, C. L. Willman, T. H. Norwood, D. S. Howard, S. E. Coutre, H. P. Erba, and F. R. Appelbaum, “A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia,” *Blood*, 122(20), pages 3432–3439, 2013. PMID: PMC3829116.
  121. W. G. Woods, A. R. Franklin, T. A. Alonzo, R. B. Gerbing, K. A. Donohue, **M. Othus**, J. Horan, F. R. Appelbaum, E. H. Estey, C. D. Bloomfield, and R. Larson, “Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials,” *Cancer*, 119(23), pages 4170–4179, 2013. PMID: PMC3833872.
  122. F. Ostronoff, **M. Othus**, H. M. Kantarjian, S. Meshinchi, F. Ravandi, P. C. Hendrie, S. Faderl, P. S. Becker, J. E. Cortes, J. M. Pagel, S. H. Petersdorf, J. E. Godwin, C. L. Willman, S. A. Pierce, A. F. List, R. K. Sandhu, R. B. Walter, D. L. Stirewalt, F. R. Appelbaum, and E. H. Estey, “A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia,” *British Journal of Haematology*, 163(1), pages 130–132, 2013. PMID: PMC4128010.
  123. T. L. Chen, E. H. Estey, **M. Othus**, K. M. Gardner, L. J. Markle, and R. B. Walter, “Cyclosporine modulation of multidrug resistance in combina-

- tion with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: A phase 1/2 study,” *Leukemia & Lymphoma*, 54(11), pages 2534–2536, 2013. PMID: PMC3863328.
124. M. Roshal, S. Chien, **M. Othus**, B. Wood, M. Fang, F. Appelbaum, E. Estey, T. Papayannopoulou, and P. Becker, “The proportion of CD34+CD38<sup>low</sup> or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia,” *Leukemia*, 27(3), pages 728–731, 2013. PMID: PMC3705906.
  125. R. B. Walter, **M. Othus**, A. K. Burnett, B. Löwenberg, H. M. Kantarjian, G. J. Ossenkoppele, R. K. Hills, K. G. van Montfort, F. Ravandi, A. Evans, S. R. Pierce, F. R. Appelbaum, and E. H. Estey, “Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: Analysis of 5848 newly diagnosed patients,” *Blood*, 121(13), pages 2424–2431, 2013. PMID: PMC3612855.
  126. A. Lin, **M. Othus**, A. McQuary, M. Chi, and E. Estey, “Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia,” *Leukemia & Lymphoma*, 54(3), pages 541–546, 2013. PMID: PMC4451200.
  127. R. C. Shelton, A. C. Snavely, M. De Jesus, **M. Othus**, and J. D. Allen, “HPV vaccine decision-making and acceptance: Does religion play a role?,” *Journal of Religion and Health*, 52(4), pages 1120–1130, 2013. PMID: 22076049.
  128. F. Ostronoff, **M. Othus**, P. Ho, M. Kutny, D. Geraghty, S. Petersdorf, J. Godwin, C. Willman, J. Radich, F. Appelbaum, D. Stirewalt, and S. Meshinchi, “Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: A SWOG report,” *Leukemia*, 27(1), pages 238–241, 2012. PMID: 22722750.
  129. J. E. Karp, E. Garrett-Mayer, E. H. Estey, M. A. Rudek, B. D. Smith, J. M. Greer, D. M. Drye, K. Mackey, K. S. Dorcy, S. D. Gore, M. Levis, M. McDewitt, H. Carraway, K. Pratz, D. Gladston, M. Showel, **M. Othus**, L. A. Doyle, J. J. Wright, and J. M. Pagel, “Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia,” *Haematologica*, 97(11), pages 1736–1742, 2012. PMID: PMC3487449.
  130. S. Bhatia, J. Moon, K. A. Margolin, J. S. Weber, C. D. Lao, **M. Othus**, A. M. Aparicio, A. Ribas, and V. K. Sondak, “Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512,” *PloS one*, 7(11), pages e48787, 2012. PMID: PMC3511501.
  131. **M. Othus**, Y. Li, and R. Tiwari, “Change-point cure models with application to estimating the change-point effect of age of diagnosis among prostate cancer patients,” *Journal of Applied Statistics*, 39(4), pages 901–911, 2012. PMID: PMC3337711.

132. R. B. Walter, **M. Othus**, and E. H. Estey, “Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment (response to letter by F. Ferrara),” *Journal of Clinical Oncology*, 30(4), pages 463–464, 2012. PMID: 22184399.
133. B. C. Medeiros, **M. Othus**, M. Fang, F. R. Appelbaum, and E. H. Estey, “Impact of residual normal metaphases in core binding factor acute myeloid leukemia,” *Cancer*, 118(9), pages 2420–2423, 2012. PMID: PMC3490403.
134. B. C. Medeiros, **M. Othus**, E. H. Estey, M. Fang, and F. R. Appelbaum, “Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia,” *Haematologica*, 97(9), pages 1401–1404, 2012. PMID: PMC3436242.
135. **M. Othus**, B. Barlogie, M. L. LeBlanc, and J. J. Crowley, “Cure models as a useful statistical tool for analyzing survival,” *Clinical Cancer Research*, 18(14), pages 3731–3736, 2012. PMID: PMC3744099.
136. K. A. Margolin, J. Moon, L. E. Flaherty, C. D. Lao, W. L. Akerley, **M. Othus**, J. A. Sosman, J. M. Kirkwood, and V. K. Sondak, “Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438),” *Clinical Cancer Research*, 18(4), pages 1129–1137, 2012. PMID: PMC3481165.
137. R. B. Walter, **M. Othus**, G. Borthakur, F. Ravandi, J. E. Cortes, S. A. Pierce, F. R. Appelbaum, H. A. Kantarjian, and E. H. Estey, “Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment,” *Journal of Clinical Oncology*, 29(33), pages 4417–4424, 2011. PMID: PMC3221524.
138. M. Fang, B. Storer, E. Estey, **M. Othus**, L. Zhang, B. M. Sandmaier, and F. R. Appelbaum, “Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation,” *Blood*, 118(6), pages 1490–1494, 2011. PMID: PMC3156042.
139. B. M. Alexander, **M. Othus**, H. B. Caglar, and A. M. Allen, “Tumor volume is a prognostic factor in non–small-cell lung cancer treated with chemoradiotherapy,” *International Journal of Radiation Oncology\* Biology\* Physics*, 79(5), pages 1381–1387, 2011. PMID: 20605346.
140. B. Xie, **M. Othus**, B. C. Medeiros, M. Fang, F. R. Appelbaum, and E. H. Estey, “Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype,” *Haematologica*, 96(4), pages 631–632, 2011. PMID: PMC3069244.
141. B. Medeiros, **M. Othus**, and F. Appelbaum, “Cytarabine dose for acute myeloid leukemia (letter),” *New England Journal of Medicine*, 364(22), pages 2167–2168, 2011. PMID: 21631340.
142. **M. Othus**, J. Moon, and K. Margolin, “Melanoma’s deadly march to the brain,” *Cancer*, 117(8), pages 1560–1563, 2011. PMID: 21472703.

143. J. D. Allen, **M. Othus**, A. Hart, A. P. Mohllajee, Y. Li, and D. Bowen, “Do men make informed decisions about prostate cancer screening? Baseline results from the “Take the Wheel” trial,” *Medical Decision Making*, 31(1), pages 108–120, 2011. PMID: PMC4386607.
144. **M. Othus** and Y. Li, “A Gaussian copula model for multivariate survival data,” *Statistics in Biosciences*, 2(2), pages 154–179, 2010. PMID: PMC3232005.
145. J. D. Allen, **M. Othus**, A. Hart, L. Tom, Y. Li, D. Berry, and D. Bowen, “A randomized trial of a computer-tailored decision aid to improve prostate cancer screening decisions: Results from the Take the Wheel trial,” *Cancer Epidemiology Biomarkers & Prevention*, 19(9), pages 2172–2186, 2010. PMID: PMC4386842.
146. J. D. Allen, **M. Othus**, R. C. Shelton, Y. Li, N. Norman, L. Tom, and M. G. del Carmen, “Parental decision making about the HPV vaccine,” *Cancer Epidemiology Biomarkers & Prevention*, 19(9), pages 2187–2198, 2010. PMID: 20826829.
147. H. B. Caglar, **M. Othus**, and A. M. Allen, “Esophagus in-field: A new predictor for esophagitis,” *Radiotherapy and Oncology*, 97(1), pages 48–53, 2010. PMID: 20832884.
148. B. C. Medeiros, **M. Othus**, M. Fang, D. Roulston, and F. R. Appelbaum, “Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience,” *Blood*, 116(13), pages 2224–2228, 2010. PMID: PMC3709629.
149. M. R. Litzow, **M. Othus**, L. D. Cripe, S. D. Gore, H. M. Lazarus, S. J. Lee, J. M. Bennett, E. M. Paietta, G. W. Dewald, J. M. Rowe, and M. S. Tallman, “Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group,” *British Journal of Haematology*, 148(2), pages 217–225, 2010. PMID: PMC2809127.
150. M. De Jesus, L. Parast, R. C. Shelton, K. Kokkinogenis, **M. Othus**, Y. Li, and J. D. Allen, “Actual vs preferred sources of human papillomavirus information among black, white, and hispanic parents,” *Archives of Pediatrics & Adolescent Medicine*, 163(11), pages 1066–1067, 2009. PMID: PMC2914618.
151. **M. Othus**, Y. Li, and R. Tiwari, “A class of semiparametric mixture cure survival models with dependent censoring,” *Journal of the American Statistical Association*, 104(487), pages 1241–1250, 2009. PMID: PMC2920213.
152. J. D. Allen, A. P. Mohllajee, R. C. Shelton, **M. Othus**, H. B. Fontenot, and R. Hanna, “Stage of adoption of the human papillomavirus vaccine among college women,” *Preventive medicine*, 48(5), pages 420–425, 2009. PMID: 19133288.
153. H. B. Caglar, E. H. Baldini, **M. Othus**, M. S. Rabin, R. Bueno, D. J. Sugarbaker, S. J. Mentzer, P. A. Jänne, B. E. Johnson, and A. M. Allen, “Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery,” *Cancer*, 115(18), pages 4156–4166, 2009. PMID: 19551884.

154. H. B. Caglar, R. B. Tishler, **M. Othus**, E. Burke, Y. Li, L. Goguen, L. J. Wirth, R. I. Haddad, C. M. Norris, L. E. Court, D. J. Aninno, M. R. Posner, and A. M. Allen, “Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy,” *International Journal of Radiation Oncology\* Biology\* Physics*, 72(4), pages 1110–1118, 2008. PMID: 19551884.
155. J. Rusby, E. Brachtel, **M. Othus**, J. Michaelson, F. Koerner, and B. Smith, “Development and validation of a model predictive of occult nipple involvement in women undergoing mastectomy,” *British Journal of Surgery*, 95(11), pages 1356–1361, 2008. PMCID: PMC3576704.
156. L. J. Wirth, J. F. Krane, Y. Li, **M. Othus**, A. E. Moran, D. M. Dorfman, C. M. Norris, L. Goguen, M. R. Posner, R. I. Haddad, and M. M. Bertagnollu, “A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions,” *Cancer Prevention Research*, 1(5), pages 339–348, 2008. PMID: 19138978.